Drug Profile
Tropifexor - Novartis
Alternative Names: LJN-452; NVP-LJN452-NXALatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Novartis
- Developer Allergan; Novartis
- Class Anti-inflammatories; Antifibrotics; Benzothiazoles; Hepatoprotectants; Oxazoles; Small molecules
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatic fibrosis; Non-alcoholic steatohepatitis; Primary bile acid malabsorption; Primary biliary cirrhosis
- No development reported Liver disorders
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for phase-I development in Liver-disorders in USA
- 21 Jun 2023 Efficacy data from the phase II FLIGHT-FXR trial in Non-alcoholic steatohepatitis presented at the 72nd European Association for the Study of the Liver Congress (EASL-2023)
- 15 Jun 2023 Efficacy data from a phase IIb TANDEM trial in Non-alcoholic steatohepatitis and and liver fibrosis released by Novartis